Senti Biosciences, Inc. (SNTI)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Next-generation Cell and Gene Therapies	2.56M
Next-generation Cell and Gene Therapies Growth	-40.25%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
United States	2.56M
United States Growth	-40.25%